DOLPAC 2
Country: Portugal
Language: English
Source: HMA (Heads of Medicines Agencies)
Patient Information leaflet
(PIL)
04-03-2012
Summary of Product characteristics
(SPC)
04-03-2012
Active ingredient:
oxantel embonate 40.06 mg, praziquantel 10 mg, pyrantel embonate 9.99 mg
Available from:
Vetoquinol
ATC code:
QP52AA51
Pharmaceutical form:
Tablet
Therapeutic group:
praziquantel, combinations
Therapeutic area:
Dogs
Authorization date:
2011-05-19
Patient Information leaflet
VETOQUINOL/DOLPAC SMALL DOGS/EUROPEAN RENEWAL
JUNE 2011
1/5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Austria
Belgium
Cyprus
Malta
Czech Republic
Netherlands
Greece
Portugal
Slovakia
Hungary
Slovenia
Germany
Finland
Dolpac small dogs tablets
France Luxembourg
Dolpac 2 comprimé
UK-Ireland-Italy
Dolpac Tablets for Small Dogs
Spain
Poland
Dolpac small dogs tablets for 1-6
kg
Denmark
Sweden
Dolpac vet small dogs tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains
Active substances
Oxantel
40.06 mg (equivalent to 111.8 mg of oxantel embonate)
Pyrantel
9.99 mg (equivalent to 28.8 mg of pyrantel embonate)
Praziquantel
10.00 mg
Excipient to one 190 mg divisible tablet
Excipients
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet
Pale yellow to yellow oblong tablet with breaking line;
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For curative treatment of dogs harbouring mixed parasitic infestations with the following adult stages
of nematode and cestode species:
Nematodes:
_ _
_Toxocara canis_
_ _
_Toxascaris leonina _
_ _
_Ancylostoma caninum_
VETOQUINOL/DOLPAC SMALL DOGS/EUROPEAN RENEWAL
JUNE 2011
2/5
_ _
_Uncinaria stenocephala _
_ _
_Trichuris vulpis_
Cestodes:
_ _
_Dipylidium caninum_
_ _
_ _
_ _
_Taenia _spp_ _
_ _
_Echinococcus multilocularis_
_ _
_Echinococcus granulosus_
4.3
CONTRAINDICATIONS
See section 4.8.
4.4
SPECIAL WARNINGS FOR E
Read the complete document
Summary of Product characteristics
VETOQUINOL/DOLPAC SMALL DOGS/EUROPEAN RENEWAL
JUNE 2011
1/10
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Austria
Belgium
Cyprus
Malta
Czech Republic
Netherlands
Greece
Portugal
Slovakia
Hungary
Slovenia
Germany
Finland
Dolpac small dogs tablets
France Luxembourg
Dolpac 2 comprimé
UK-Ireland-Italy
Dolpac Tablets for Small Dogs
Spain
Poland
Dolpac small dogs tablets for 1-6
kg
Denmark
Sweden
Dolpac vet small dogs tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains
Active substances
Oxantel
40.06 mg (equivalent to 111.8 mg of oxantel embonate)
Pyrantel
9.99 mg (equivalent to 28.8 mg of pyrantel embonate)
Praziquantel
10.00 mg
Excipient to one 190 mg divisible tablet
Excipients
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet
Pale yellow to yellow
, elongated, divisible oblong
tablet
with breaking line;
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For curative treatment of dogs harbouring mixed parasitic infestations with the following adult stages
of nematode and cestode species:
Nematodes:
_ _
_Toxocara canis_
_ _
_Toxascaris leonina _
_ _
_Ancylostoma caninum_
VETOQUINOL/DOLPAC SMALL DOGS/EUROPEAN RENEWAL
JUNE 2011
2/10
_ _
_Uncinaria stenocephala _
_ _
_Trichuris vulpis_
Cestodes:
_ _
_Dipylidium caninum_
_ _
_ _
_ _
_Taenia _spp_ _
_ _
_Echinococcus multilocularis_
_ _
_Echinococcus granulosus_
4.3
CONTRAINDICATIONS
See section 4.8.
Read the complete document
